A1,
A2,
B,
C1,
C2,
D,
E,
F,
G-H,
I-K,
L,
M,
N,
O,
P1,
P2,
Q-R,
S,
T,
U-V,
W-Z
Bacitracin Warnings, Precautions, Pregnancy, Nursing, Abuse - Bacitracin
Bacitracin Warnings, Precautions, Pregnancy, Nursing, Abuse - Bacitracin
WARNING
Nephrotoxicity: Bacitracin in parenteral (intramuscular) therapy may
cause renal failure due to tubular and glomerular necrosis. Its use
should be restricted to infants with staphylococcal pneumonia and
empyema when due to organisms shown to be susceptible to bacitracin.
It should be used only where adequate laboratory facilities are available
and when constant supervision of the patient is possible.
Renal function should be carefully determined prior to and daily
during therapy. The recommended daily dose should not be exceeded
and fluid intake and urinary output maintained at proper levels to avoid
kidney toxicity. If renal toxicity occurs the drug should be discontinued.
The concurrent use of other nephrotoxic drugs, particularly streptomycin,
kanamycin, polymyxin B, polymyxin E (colistin), and neomycin
should be avoided.
PRECAUTIONS
See "Warning" for precautions in regard to kidney toxicity associated with
intramuscular use of bacitracin.
Adequate fluid intake should be maintained orally, or if necessary, by parenteral
method.
As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible
organisms, including fungi. If superinfection occurs, appropriate therapy
should be instituted.
Prescribing Bacitracin in the absence of a proven or strongly suspected bacterial
infection or a prophylactic indication is unlikely to provide benefit to the
patient and increases the risk of the development of drug-resistant bacteria.
top
